Common drug tested for stubborn skin disease
NCT ID NCT07286604
Summary
This small, early study tested if the drug ivermectin, taken by mouth, is safe and can help treat Post Kala-Azar Dermal Leishmaniasis (PKDL). PKDL is a skin condition that can appear after someone recovers from kala-azar (visceral leishmaniasis). The study involved 10 participants in Bangladesh who took ivermectin daily for five days each month, for three months, and were followed for six months to check for side effects and see if their skin lesions improved.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST KALA-AZAR DERMAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, 1212, Bangladesh
Conditions
Explore the condition pages connected to this study.